Table 1.
Representative clinical reports and studies of BNCT for meningiomas.
| Authors | Country | Published Year | No. of Patient with a Meningioma (WHO Grade) | Boron Compound | Research Target or Content | Reference |
|---|---|---|---|---|---|---|
| Takeuchi, et al. | Japan | 2018 | 33 (12 grade II, 21 grade III) | BPA, BSH, 18F-BPA | Patients with skull base HGMs | [20] |
| Beshr, et al. | Japan | 2018 | 1 (ND) | 18F-BPA | 18F-BPA -PET | [21] |
| Kulvik, et al. | Finland | 2015 | 3 (3 grade I) | BPA | Biodistribution of boron | [22] |
| Kageji, et al. | Japan | 2015 | 1 (ND) | BPA, BSH, 18F-BPA | Radiation-induced meningioma after BNCT | [23] |
| Kawaji, et al. | Japan | 2014 | 1 (grade III) | BPA, BSH, 18F-BPA | An autopsy case after BNT | [24] |
| Kawabata, et al. | Japan | 2013 | 20 (4 grade II, 16 grade III) | BPA, BSH, 18F-BPA | Patients with recurrent HGMs | [25] |
| Aiyama, et al. | Japan | 2011 | 1 (grade III) | BPA, 18F-BPA | A case of MM | [26] |
| Miyatake, et al. | Japan | 2009 | 13 (MM) | BPA, BSH, 18F-BPA | Pseudoprogression in patients after BNCT | [27] |
| Miyatake, et al. | Japan | 2007 | 7 (1 grade II, 6 grade III) | BPA, BSH, 18F-BPA | Patients with HGMs | [28] |
| Stenstam, et al. | Sweden | 2007 | 3 (1 grade II, 2 grade III) | BPA | Accumulation of boron | [29] |
| Havu-Aurén, et al. | Finland | 2007 | 4 (ND) | 18F-BPA | 18F-BPA -PET | [18] |
| Tamura, et al. | Japan | 2006 | 1 (1 grade III) | BPA, BSH, 18F-BPA | The first case of MM treated by BNCT | [30] |
| Miyatake, et al. | Japan | 2006 | 11 (11 grade III) | BPA, BSH, 18F-BPA | Patients with MM | [31] |
| Stragliotto, et al. | Switzerland | 1995 | 14 (ND) | BSH | Biodistribution of boron | [15] |
| Kraft, et al. | USA | 1994 | 8 animal models (ND) | BSH | Biodistribution of boron | [14] |
BPA, boronophenylalanine; BSH, sulfhydryl borane; 18F-BPA, 18F-boronophenylalanine; HGM, high-grade meningioma; PET, positron emission tomography; MM, malignant meningioma; U.S.A., United States of America.